Company*
(Country; Symbol)
Company
(Country; Symbol)
Type/Product AreaTerms/Details (Date)

I. MODIFIED AGREEMENTS
Argenta Discovery Ltd.* (UK)Genentech Inc. (NYSE:DNA)Contract drug discovery agreement extended for two more yearsThe project uses Argenta's expertise in computer-aided drug design, medicinal chemistry and in vitro biology and screening to discover new chemical entities acting against undisclosed targets (10/24)
Dyax Corp. (DYAX)ImClone Systems Inc. (IMCL)Expanded antibody library collaboration giving ImClone access to Dyax's phage display technology for an additional four yearsDyax will continue to receive annual license fees as well as potential milestones and royalties (11/8)
MorphoSys AG (Germany; FSE: MOR)GeneFrontier Corp.* (Japan)Collaboration that expands an existing alliance and aims to increase MorphoSys' access to druggable therapeutic targets from leading Japanese research institutes and universitiesFinancial details were not disclosed (12/11)
II. TERMINATED AGREEMENTS
Infinity Pharmaceuticals Inc. (INFI)MedImmune Inc. (LSE:MDI; unit of Astra-Zeneca plc; UK)Terminated agreement for the worldwide development and commercialization rights to Infinity's Hedgehog cell-signaling pathway inhibitor program, including its lead candidate IPI-926The deal was terminated because Med-Immune's parent company, AstraZeneca, has a competing program (11/12)
Novavax Inc. (NVAX)Allergan Inc. (NYSE:AGN)Terminated manufacturing supply agreement for EstrasorbNovavax will complete the manufacture of remaining orders and plans to close its Philadelphia manufacturing facility over the next few months (10/25)

Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

No Comments